SHENZHEN, CHINA, Feb. 14, 2025 — China Medical System Holdings Limited (“CMS” or the “Group”) has been named in the S&P Global Sustainability Yearbook 2025 (the “Yearbook 2025”). Achieving a Corporate Sustainability Assessment (CSA) score of 61, exceeding 93% of its global competitors, this marks the Group’s first appearance in the global S&P Global Sustainability Yearbook, following two consecutive years of inclusion in the China edition.

The Yearbook, launched in 2008, is widely respected by global ESG investors and stakeholders for its professionalism and authority. It identifies leading companies in sustainable development across industries. Of the 7,690 companies assessed across 62 industries, only 780 made the Yearbook 2025. CMS’s inclusion reflects a high level of recognition for its sustainable practices.

CMS has actively aligned with the UN Sustainable Development Goals (SDGs) for years, integrating ESG governance into its corporate strategy and developing a comprehensive ESG strategy. The Group continually invests in innovation to improve access to cutting-edge diagnostic and treatment technologies and actively fulfills its social responsibilities to create value across business, industry, and society. This sustainability performance is supported by several authoritative ESG rating agencies. CMS maintains an “AA” MSCI ESG rating, ranks in the top 10% of its industry for the Hong Kong Quality Assurance Agency (HKQAA) sustainability rating, and holds an “AA” Sino-Securities Index ESG rating.

Looking ahead, with an ESG vision of becoming a world-leading sustainable pharmaceutical enterprise, CMS will strengthen its corporate governance, social contributions, and environmental protection efforts. The company will collaborate with stakeholders to promote sustainable development and contribute to a more sustainable planet.

About CMS
CMS is a platform company connecting pharmaceutical innovation and commercialization, possessing strong product lifecycle management capabilities. It is dedicated to providing competitive products and services to address unmet medical needs.

CMS focuses on global first-in-class (FIC) and best-in-class (BIC) innovative products. It efficiently advances the clinical research, development, and commercialization of innovative products, translating scientific research into clinical practice for patient benefit.

CMS is deeply involved in several specialty therapeutic areas and has developed robust commercialization capabilities, extensive networks, and expert resources, resulting in leading academic and market positions for its key products. CMS is further developing its advantageous specialty areas and expanding its business scope. While strengthening its cardio-cerebrovascular/gastroenterology business, CMS operates independent dermatology and medical aesthetics, and ophthalmology businesses, aiming for leadership in specialty therapeutic areas and enhancing scale and efficiency. Simultaneously, CMS has expanded into Southeast Asia, aiming to be a gateway for global pharmaceutical companies entering the region and supporting the Group’s sustainable and healthy development.

CMS Disclaimer and Forward-Looking Statements
This press release is not intended for product promotion or advertising. It does not recommend any drugs, medical devices, and/or indications. For specific disease diagnosis and treatment information, consult your doctor or other healthcare professionals. Healthcare professionals should base treatment decisions on individual patient circumstances and the drug package insert.

This press release, prepared by CMS, does not constitute an offer or invitation to purchase or subscribe to any securities and should not be relied upon in connection with any contract or commitment. CMS prepared this release based on information it considers reliable, but makes no representations or warranties, express or implied, regarding the truth, accuracy, completeness, fairness, or reasonableness of its contents. Certain matters discussed may contain forward-looking statements regarding the Group’s market opportunity and business prospects. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions that are difficult to predict. Any forward-looking statements and projections from third parties are not adopted by the Group, and the Company is not responsible for them.

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email:

Website:

Source: China Medical System Holdings Ltd.